First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.

@article{Lusher2002FirstAS,
  title={First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.},
  author={J. Lusher},
  journal={Seminars in thrombosis and hemostasis},
  year={2002},
  volume={28 3},
  pages={
          273-6
        }
}
  • J. Lusher
  • Published 2002 in Seminars in thrombosis and hemostasis
The first of the prospective multicenter studies in previously untreated patients (PUPs) with a recombinant factor VIII (FVIII) concentrate began in January 1989. Over the past 11 years, PUP studies have amassed a great deal of information concerning safety, efficacy, and inhibitor development of the two "first-generation" recombinant (r) FVIII concentrates (Kogenate and Recombinate) and of two "second-generation" products (ReFacto and Kogenate FS, which is formulated with sucrose rather than… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Inhibitors in congenital coagulation disorders.

British journal of haematology • 2004
View 5 Excerpts
Highly Influenced

Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?

Haemophilia : the official journal of the World Federation of Hemophilia • 2009

Recombinant clotting factors.

Thrombosis and haemostasis • 2008

Similar Papers

Loading similar papers…